Expediting a pediatric vaccine trial through site- and participant-centric practices

In collaboration with Labcorp Drug Development and academic investigators, a large pharmaceutical company launched a study to prevent respiratory syncytial virus (RSV), a common seasonal virus that often has mild symptoms but can cause hospitalization and death in newborns and infants. The Phase IIIb study aimed to recruit more than 25,000 newborns and infants across 250 sites in Europe and gather additional data to assess if their asset prevents lower respiratory tract infection (LRTI) caused by RSV requiring medical attention and seek EU-wide marketing authorization.